中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | HB011317 |
|---|---|
| 種反応性 | Human |
| アプリケーション | ELISA, FCM |
| 宿主種 | Mouse |
| クローン性 | Monoclonal |
| アイソタイプ | IgG1, kappa |
| クローンID | RFB-4 |
| 抱合 | FITC |
| テスト済みアプリケーション | FCM |
| ターゲット | B-cell receptor CD22, B-lymphocyte cell adhesion molecule, BL-CAM, CD22, SIGLEC2, Sialic acid-binding Ig-like lectin 2, Siglec-2, T-cell surface antigen Leu-14 |
| エンドトキシンレベル | Please contact with the lab for this information. |
| 純度 | >90% as determined by SDS-PAGE. |
| 関連製品 | Mouse IgG1, kappa Recombinant Isotype Control Antibody (MOPC-21), FITC |
| アクセッション番号 | P20273 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS, pH 7.4, 50% glycerol, 0.05% Proclin 300. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Store at 4°C for 12 months. Protect from light. Do not freeze. |
| 背景 | B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa). 1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755 2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166 3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905 4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366 |
| 参考文献 | 1. Kreitman RJ, et al. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer. 1999 Mar 31;81(1):148-55. [HB011317] 2. Mansfield E, et al. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90(5):2020-2026. [HB011317] |
| 注意事項 | For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only. |
Flow-cytometry using FITC anti-human CD22 antibody. Daudi cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD22 monoclonal antibody (Catalog: HB011317, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, and cells analysed on a NovoCyte Flow Cytometer.
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
